Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

European Haematology Association

- PMLiVE

J&J files ‘breakthrough’ drug ibrutinib in US

FDA to assess drug in lymphoma and leukaemia

- PMLiVE

Revlimid faces NICE rejection for use in rare blood cancer

Watchdog's draft guidance does not recommend Celgene's drug for NHS use in England and Wales

- PMLiVE

Ariad gets EU green light for leukaemia drug Iclusig

EC approves drug in two forms of the blood cancer

Roche - Basel

Roche’s blood cancer antibody wins priority review in US

Obinutuzumab is fast-tracked by FDA in treatment of chronic lymphocytic leukaemia

- PMLiVE

Roche pays $220m for blood-testing company

Boosts diagnostics business with acquisition of Constitution Medical Investors

- PMLiVE

BMS appoints Dinesh Paliwal to board

He is CEO of audio firm Harman International

- PMLiVE

Setback for AZ and BMS as Onglyza flunks cardiovascular trial

Diabetes drug fails to show benefit over placebo

- PMLiVE

AbbVie: UK patients want better arthritis care

Study from Humira manufacturer concludes that UK doctors need better collaboration with patients

- PMLiVE

Elotuzumab on track for multiple myeloma

BMS and AbbVie present phase II results at European Haematology Association meeting

Novartis building

Jakavi shows long-term survival benefit in myelofibrosis

Trial demonstrates Novartis’ blood cancer drug cut risk of death by half over three years

- PMLiVE

BMS partners with Simcere to market arthritis drug Orencia SC in China

Builds on existing cancer/ cholesterol alliance between pharma companies

- PMLiVE

BMS’ Orencia matches Humira in arthritis study

Data should help drug establish itself against AbbVie's market-leading RA medicine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links